Evidence map›Paper›PMID 38406530›Full record

ArticleEJHaem2024

A case of benign immunoglobulin D monoclonal gammopathy of undetermined significance with 26 years of follow-up.

Larry D Anderson, Joan Bladé, Robert A Kyle

Open access · diamondAbstract readCase Reports
In one paragraph

Article in EJHaem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Larry D AndersonMyeloma, Waldenstrom's, and Amyloidosis Program Hematologic Malignancies and Cellular Therapy Program Simmons Comprehensive Cancer Center UT Southwestern Medical Center Dallas Texas USA.ORCID https://orcid.org/0000-0002-6531-9595
Joan BladéDepartment of Hematology Amyloidosis and Myeloma Unit Institut d'Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic de Barcelona University de Barcelona Barcelona Spain.
Robert A KyleDivision of Hematology Mayo Clinic Rochester Minnesota USA.
Hospital Clínic de Barcelona · ESMayo Clinic · USSouthwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of a serum immunoglobulin D (IgD) monoclonal protein (M-protein) is seen in < 1% of patients with monoclonal gammopathies and is usually indicative of a malignant plasma cell disorder. Only a few cases of well-documented benign monoclonal gammopathy of undetermined significance (MGUS) of IgD subtype have been reported, and only 2 of those had over 5 years of follow-up at the time they were reported. Herein we describe longer-term follow-up of one of those 2 patients who has subsequently passed away from unrelated causes but never developed multiple myeloma or amyloidosis after 26 years of follow-up. Although IgD MGUS is extremely rare, this case confirms that presence of an IgD M-Protein is not always synonymous with a malignant plasma cell process.

Indexed as

Immunoglobulin D (IgD)MGUSmonoclonal gammopathy

Identifiers

PMID38406530
PMCPMC10887259
OpenAlexW4390702843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.